Authors:
Wiseman, GA
White, CA
Stabin, M
Dunn, WL
Erwin, W
Dahlbom, M
Raubitschek, A
Karvelis, K
Schultheiss, T
Witzig, TE
Belanger, R
Spies, S
Silverman, DHS
Berlfein, JR
Ding, E
Grillo-Lopezs, AJ
Citation: Ga. Wiseman et al., Phase I/II Y-90-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma, EUR J NUCL, 27(7), 2000, pp. 766-777
Authors:
Wiseman, GA
White, CA
Witzig, TE
Gordon, LI
Emmanouilides, C
Raubitschek, A
Janakiraman, N
Gutheil, J
Schilder, RJ
Spies, S
Silverman, DHS
Grillo-Lopez, AJ
Citation: Ga. Wiseman et al., Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a Y-90-labeled anti-CD20 monoclonal antibody, CLIN CANC R, 5(10), 1999, pp. 3281S-3286S
Authors:
Witzig, TE
White, CA
Wiseman, GA
Gordon, LI
Emmanouilides, C
Raubitschek, A
Janakiraman, N
Gutheil, J
Schilder, RJ
Spies, S
Silverman, DHS
Parker, E
Grillo-Lopez, AJ
Citation: Te. Witzig et al., Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsedor refractory CD20(+) B-cell non-Hodgkin's lymphoma, J CL ONCOL, 17(12), 1999, pp. 3793-3803